Bio-Rad Laboratories (BIO) stock went up by 2.73% following a projected fair value estimate of US$452 based on a two-stage free cash flow to equity model, which indicates that the company is trading at a similar level to its fair value estimate.
The article does not mention why Bio-Rad Laboratories (BIO) stock went down as it is discussing breast cancer research involving TNBC subtypes and cell motility.
The article is about Wiley, one of the world's largest publishers, releasing its third-quarter results, which were below expectations due to unpredictable market headwinds, resulting in a reduction of its fiscal year 2023 outlook; therefore, it is unclear why Bio-Rad Laboratories' stock went up.
Bio-Rad Laboratories' stock (BIO) has climbed 5.76% after a recent study showed that genomics-based precision medicine could be possible for a subset of chemotherapies. The study identified KRAS codon G12 mutations as a potential biomarker of resistance in patients with metastatic colorectal cancer treated with the chemotherapy trifluridine/tipiracil (FTD/TPI), and validated the findings in a real-world cohort and a phase 3 clinical trial, potentially benefiting around 28% of patients with mCRC under consideration for treatment with FTD/TPI.
Bio-Rad Laboratories' (BIO) stock went up by 5.76% after the announcement of the expansion of a strategic partnership with Myriad Genetic (MYGN) to increase access to cancer testing.
Cytek Biosciences' stock price went down because the company had a strong earnings report and expectations for continued growth, but the stock price has since fallen by a large amount.
Bio-rad Laboratories(BIO) stock goes down because the company is facing increasing competition from Roche Diagnostics and GE Healthcare.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in life science research and clinical diagnostic products. Management will participate in a Citi's Healthcare Services, MedTech, Tools & HCIT Conference fireside chat event on March 2, 2023. This news is likely to positively affect the stock price.
The company produces medical products and conducts medical research.
The company released better-than-expected earnings reports.
Cytek and Bio-Rad have entered into a partnership to develop reagents for high-parameter applications on Aurora and Northern Lights flow cytometers.
The release of industry data by Singular Genomics which validates the performance and plug-and-play capability of the G4 across multiple applications, likely decreases the stock price of Bio-rad Laboratories.
The company produces and distributes diagnostic equipment used in the medical and life science industries.
the life sciences company reported disappointing quarterly results